NCT00562614View on ClinicalTrials.gov

Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Hypertension
Interventions
DRUG

SLx-2101

Trial Locations (1)

D-14050

Parexel, Institute for Clinical Pharmacology, Berlin

Sponsors
All Listed Sponsors
lead

Response Pharmaceuticals

INDUSTRY

NCT00562614 - Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension | Biotech Hunter | Biotech Hunter